Management of tardive dyskinesia and tardive dystonia with clozapine: A retrospective study

IF 3.8 4区医学 Q1 PSYCHIATRY

Asian journal of psychiatry Pub Date : 2024-09-13 DOI:10.1016/j.ajp.2024.104245

Sandeep Grover, Nishtha Chaurasia, Subho Chakrabarti

{"title":"Management of tardive dyskinesia and tardive dystonia with clozapine: A retrospective study","authors":"Sandeep Grover, Nishtha Chaurasia, Subho Chakrabarti","doi":"10.1016/j.ajp.2024.104245","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>This retrospective study aimed to evaluate the long-term effectiveness of switching to clozapine in the management of tardive syndromes (TS).</p></div><div><h3>Methodology</h3><p>The treatment records of patients who had TS at the time of starting clozapine, were reviewed and demographic and clinical data was extracted on a predesigned performa.</p></div><div><h3>Results</h3><p>About three-fourth (74.2 %) of the study subjects had tardive dystonias and two-third (69.7 %) had tardive dyskinesia at the time of starting clozapine. About half (48.5 %) of the patients had both tardive dystonia and dyskinesia. A small proportion (13.6 %) also had tardive akathisia at the time of starting clozapine. About three-fourth (72.2 %) of the patients had >50 % reduction, and about two-third (66.6 %) of the patients had >75 % reduction and nearly half (54.5 %) of the patients had complete resolution of dyskinesia at the last follow-up. Similar trends were seen in reduction in dystonia, i.e., >50 % reduction in 74.3 %, >75 % reduction in 62.2 % and complete resolution was seen in 56.1 %.</p></div><div><h3>Conclusions</h3><p>The present study suggest that clozapine is useful in the management of drug induced tardive dyskinesia and tardive dystonia.</p></div>","PeriodicalId":8543,"journal":{"name":"Asian journal of psychiatry","volume":"102 ","pages":"Article 104245"},"PeriodicalIF":3.8000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian journal of psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1876201824003381","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

This retrospective study aimed to evaluate the long-term effectiveness of switching to clozapine in the management of tardive syndromes (TS).

Methodology

The treatment records of patients who had TS at the time of starting clozapine, were reviewed and demographic and clinical data was extracted on a predesigned performa.

Results

About three-fourth (74.2 %) of the study subjects had tardive dystonias and two-third (69.7 %) had tardive dyskinesia at the time of starting clozapine. About half (48.5 %) of the patients had both tardive dystonia and dyskinesia. A small proportion (13.6 %) also had tardive akathisia at the time of starting clozapine. About three-fourth (72.2 %) of the patients had >50 % reduction, and about two-third (66.6 %) of the patients had >75 % reduction and nearly half (54.5 %) of the patients had complete resolution of dyskinesia at the last follow-up. Similar trends were seen in reduction in dystonia, i.e., >50 % reduction in 74.3 %, >75 % reduction in 62.2 % and complete resolution was seen in 56.1 %.

Conclusions

The present study suggest that clozapine is useful in the management of drug induced tardive dyskinesia and tardive dystonia.

查看原文本刊更多论文

用氯氮平治疗迟发性运动障碍和迟发性肌张力障碍：回顾性研究

方法回顾了开始使用氯氮平治疗时患有TS的患者的治疗记录，并根据预先设计的表格提取了人口统计学和临床数据。结果约四分之三（74.2%）的研究对象在开始使用氯氮平治疗时患有迟发性肌张力障碍，三分之二（69.7%）患有迟发性运动障碍。约半数患者（48.5%）同时患有迟发性肌张力障碍和运动障碍。一小部分患者（13.6%）在开始服用氯氮平时还伴有迟发性运动障碍。约四分之三（72.2%）的患者在最后一次随访中运动障碍症状减轻了 50%，约三分之二（66.6%）的患者减轻了 75%，近一半（54.5%）的患者运动障碍症状完全消失。在肌张力障碍的缓解方面也出现了类似的趋势，即74.3%的患者缓解了50%，62.2%的患者缓解了75%，56.1%的患者完全缓解了肌张力障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian journal of psychiatry Medicine-Psychiatry and Mental Health

CiteScore

12.70

自引率

5.30%

发文量

297

审稿时长

35 days

期刊介绍： The Asian Journal of Psychiatry serves as a comprehensive resource for psychiatrists, mental health clinicians, neurologists, physicians, mental health students, and policymakers. Its goal is to facilitate the exchange of research findings and clinical practices between Asia and the global community. The journal focuses on psychiatric research relevant to Asia, covering preclinical, clinical, service system, and policy development topics. It also highlights the socio-cultural diversity of the region in relation to mental health.